Liver health may change how this drug works
NCT ID NCT06916078
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how lepodisiran enters the blood and leaves the body in people with mild, moderate, or severe liver problems compared to those with healthy livers. About 33 adults will receive a single injection under the skin. The goal is to understand how liver function affects the drug and what side effects may occur.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
American Research Corporation at Texas Liver Institute
San Antonio, Texas, 78215, United States
-
CRU Early Phase Unit
Kistarcsa, H-2143, Hungary
-
Clinical Pharmacology of Miami
Miami, Florida, 33014-3616, United States
-
Orlando Clinical Research Center
Orlando, Florida, 32809, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test